Buckingham Maintained Azul (AZUL) As Buy; Has Target Price per Share Of $30; Cumberland Pharmaceuticals (CPIX) Sentiment Is 0.69

June 16, 2018 - By Kurt Siggers

They currently have a $30 target price per share on Azul (AZUL). Buckingham’s target would suggest a potential upside of 62.51% from the company’s last stock close price. This was revealed in a note on 13 June.

Cumberland Pharmaceuticals Inc (CPIX) investors sentiment decreased to 0.69 in 2018 Q1. It’s down -0.17, from 0.86 in 2017Q4. The ratio has dropped, as 9 hedge funds started new or increased holdings, while 13 reduced and sold their stock positions in Cumberland Pharmaceuticals Inc. The hedge funds in our database now own: 4.09 million shares, down from 4.12 million shares in 2017Q4. Also, the number of hedge funds holding Cumberland Pharmaceuticals Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 9 Increased: 8 New Position: 1.

Analysts await Azul S.A. (NYSE:AZUL) to report earnings on August, 13. They expect $-0.22 EPS, down 120.00% or $0.12 from last year’s $-0.1 per share. After $0.57 actual EPS reported by Azul S.A. for the previous quarter, Wall Street now forecasts -138.60% negative EPS growth.

Azul S.A. operates as an airline company in Brazil. The company has market cap of $1.98 billion. It provides passenger and cargo air transportation services. It has a 12.38 P/E ratio. As of September 30, 2017, the firm operated 755 daily flights to 104 destinations through a network of 197 non-stop routes with a fleet of 118 aircraft.

The stock decreased 2.07% or $0.39 during the last trading session, reaching $18.46. About 654,836 shares traded. Azul S.A. (AZUL) has risen 0.13% since June 16, 2017 and is uptrending. It has underperformed by 12.44% the S&P500. Some Historical AZUL News: 29/03/2018 – Azul brings Paris closer than ever; 08/03/2018 – AZUL SA – CAPACITY INCREASES (ASKS) 15.2% IN FEB; 10/05/2018 – Azul Reports April Traffic; 17/04/2018 – EXCLUSIVE-Amazon in talks with airline Azul for shipping in Brazil; 09/03/2018 – AZUL SA AZUL.N : DEUTSCHE BANK RAISES TARGET PRICE TO $37 FROM $31; 10/05/2018 – Azul 1Q Passenger Traffic Increased 13.4%; 17/04/2018 – Amazon in talks with airline Azul to ship across Brazil; 10/05/2018 – Azul: April Load Factor Was 81.4%, Down 0.3 Percentage Point; 27/04/2018 – United Airlines increases economic stake in Azul to 8.0%; 11/04/2018 – AZUL SA – ANNOUNCES THE LEASE OF TWO USED BOEING 737-400F TO SUPPORT THE RAPID GROWTH OF ITS CARGO BUSINESS UNIT, AZUL CARGO EXPRESS – SEC FILING

More notable recent Azul S.A. (NYSE:AZUL) news were published by: Seekingalpha.com which released: “Azul: When Will The Slump End?” on June 11, 2018, also Seekingalpha.com with their article: “Azul’s May Traffic Report Could Have Been Much Worse” published on June 12, 2018, Globenewswire.com published: “New Research Coverage Highlights Ichor, SCANA, Pattern Energy Group, Arthur J. Gallagher, Premier, and Azul …” on June 15, 2018. More interesting news about Azul S.A. (NYSE:AZUL) were released by: Fool.com and their article: “Why Petroleo Brasileiro, Companhia Siderurgica, and Azul SA Stocks Collapsed Yesterday” published on June 08, 2018 as well as Prnewswire.com‘s news article titled: “Azul Reports May Traffic” with publication date: June 11, 2018.

Among 2 analysts covering Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Azul S.A. American Depositary Shares (each representing three preferred shares) has $38.0 highest and $30 lowest target. $34’s average target is 84.18% above currents $18.46 stock price. Azul S.A. American Depositary Shares (each representing three preferred shares) had 5 analyst reports since August 7, 2017 according to SRatingsIntel. Buckingham Research maintained the stock with “Buy” rating in Friday, March 9 report. The rating was maintained by Buckingham Research on Monday, September 25 with “Buy”. On Friday, February 16 the stock rating was initiated by UBS with “Buy”. The firm has “Buy” rating by Buckingham Research given on Wednesday, June 13. On Monday, August 7 the stock rating was maintained by Buckingham Research with “Buy”.

The stock increased 2.39% or $0.14 during the last trading session, reaching $6.01. About 11,362 shares traded. Cumberland Pharmaceuticals Inc. (CPIX) has declined 14.79% since June 16, 2017 and is downtrending. It has underperformed by 27.36% the S&P500. Some Historical CPIX News: ; 04/04/2018 – Rhode Island DoA: Cumberland School Committee Wed, 4/4/2018, 6:15 PM; 03/04/2018 – Cumberland Pharmaceuticals Access Event Set By FBR for Apr. 10; 15/04/2018 – Thrift Wins FLW Tour at Lake Cumberland presented by General Tire; 06/03/2018 – Cumberland Pharma 4Q Adj EPS 3c; 07/05/2018 – Cumberland Pharmaceuticals Appoints New Senior Executive; 21/03/2018 – Cumberland’s Eisenbeis Sees Unusual Fed Rate Path (Video); 04/04/2018 – Rhode Island DoA: Cumberland Ordinance Sub-Committee Wed, 4/4/2018, 7:00 PM; 09/04/2018 – S&PGR Asgns Prelim Rtg To 1 Class From Cumberland Park CLO Ltd; 18/04/2018 – Pennsylvania’s Cumberland Valley Campaigns to Keep ltself Off the Map; 15/03/2018 – Rhode Island DoA: Cumberland School Committee Thu, 3/15/2018, 6:45 PM

Jw Asset Management Llc holds 1.18% of its portfolio in Cumberland Pharmaceuticals Inc. for 178,942 shares. Bard Associates Inc owns 83,215 shares or 0.28% of their US portfolio. Moreover, Ariel Investments Llc has 0.08% invested in the company for 1.01 million shares. The Texas-based Bridgeway Capital Management Inc has invested 0.02% in the stock. Delta Asset Management Llc Tn, a Tennessee-based fund reported 11,000 shares.

Analysts await Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) to report earnings on August, 14. They expect $-0.08 EPS, down 14.29% or $0.01 from last year’s $-0.07 per share. After $-0.11 actual EPS reported by Cumberland Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -27.27% EPS growth.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. The company has market cap of $94.42 million. It marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. It currently has negative earnings. The companyÂ’s product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: